CD38-SADA is a targeted radiotherapy delivering fixed doses of 177Lu-DOTA, a chelated complex of a lutetium radioisotope and dotatate, which leads to targeted emission of ionizing beta radiation against CD38+ malignant cells, resulting in DNA damage and associated cancer cell death. The gene discussed is CD38; the disease is cancer.